A lterations in diastolic myocardial mechanics, such as slowed left-ventricular relaxation and elevated left-ventricular stiffness, cause diastolic dysfunction and can lead to heart failure (HF). 1 Diastolic left-ventricular stiffness is determined, among others, by the extracellular matrix and the cardiomyocytes, 2 and both components can be stiffer than normal in HF, particularly in HF with preserved ejection fraction (HFpEF). 3, 4 In cardiomyocytes, passive stiffness (F passive ) is attributable largely to the giant elastic protein titin. 2 The mechanical properties of titin are altered in HF, including human HF with reduced ejection fraction (HFrEF) and HFpEF. 3,5-10
Titin, with a molecular mass up to 3800 kDa, 11 spans halfsarcomeres from the Z-disk to the M-band and functions as a molecular spring supporting early diastolic recoil and late diastolic resistance to stretch. 12, 13 Titin is also involved in myocyte mechanosensing via multiple interactions with signaling molecules. [12] [13] [14] Two main titin-isoform classes are expressed in the mammalian heart, N2B (3000 kDa) and N2BA (>3200 kDa). The titin isoforms, generated by alternative splicing, differ greatly in the molecular length of their elastic segment located in the sarcomeric I-band. 11 This segment comprises 3 extensible molecular spring elements 15 : immunoglobulin (Ig)-like domain regions; a PEVK-domain (rich in proline, glutamate, valine, and lysine); and a unique sequence within the cardiacspecific N2B element, the titin N2B-unique sequence (N2Bus). N2BA isoforms also contain an N2A domain and a variable number of additional Ig-domains and PEVK-residues. 11 Thus, the N2BA isoforms are larger and more compliant than the N2B isoform. [11] [12] [13] The cardiac N2BA:N2B expression ratio is increased in end-stage human HFrEF, concominant with a decrease in myofibrillar F passive . 5, 6, 10 In HFpEF patients, the N2BA:N2B ratio appears to be lower than in HFrEF. 3, 7 Cardiomyocyte F passive can also be modulated by posttranslational modification of I-band titin, such as disulfide bonding 16 and phosphorylation. A chronic titin-phosphorylation deficit has been detected in HFrEF and HFpEF human hearts. [7] [8] [9] Titin is phosphorylated by multiple kinases, with different effects on F passive . 7, 8, [17] [18] [19] [20] [21] The cardiac N2Bus spring element is phosphorylated by protein kinase (PK)A, 8, 17, 19, 20 cGMP-dependent PKG, 8 and extracellular signal-regulated kinase 2 (ERK2), 21 and this modification reduces F passive . 3, 7, 8, 19, 21 We provided evidence that activation of cGMP-PKG in a large animal model of HFpEF amplifies titin phosphorylation, lowers F passive , and improves diastolic function. 22 In contrast, a PEVK-portion constitutively expressed in full-length titins is phosphorylated by PKCα, and this modification increases F passive . 18 Thus, acute changes in titin-based stiffness via titin phosphorylation can occur in opposite directions, depending on which signaling pathway is activated.
Another kinase we considered to possibly phosphorylate titin is Ca 2+ /calmodulin-dependent PK-II (CaMKII). The CaMKIIδ isoform predominates in the heart, with splice variant CaMKIIδC localizing to the cytosol, 23 and CaMKIIγ is also expressed. 24 CaMKII affects myocyte functions by phosphorylating ion channels and Ca 2+ -handling proteins, and by modulating transcriptional activity. 23, [25] [26] [27] [28] Phosphorylation of histone deacetylases by CaMKII results in cardiac hypertrophic growth. 25 CaMKII isoforms show increased expression/activity in failing human hearts and in animal models of cardiac hypertrophy. [26] [27] [28] Overexpression of CaMKIIδC in mouse myocardium is associated with massive cardiac hypertrophy and induces dilated cardiomyopathy and premature death. 29 Knocking out the CaMKIIδ-isoform in mice attenuates pathological cardiac hypertrophy and remodeling in response to pressure overload. 30, 31 Inhibition of CaMKIIδ improves cardiac function and delays the onset of maladaptive remodeling, 32, 33 suggesting that CaMKII-inhibition may be a therapeutic option to treat chronic overload-induced heart disease. 23, 27 At the cardiac myofilament level, CaMKII phosphorylates myosin-binding protein-C and troponin-I, alters the rates of force development and relaxation, and modulates calcium sensitivity. [34] [35] [36] [37] In this study, we demonstrate that CaMKIIδ indeed phosphorylates cardiac titin and affects diastolic function by altering titin-based stiffness. We identify various CaMKII-dependent phosphosites along titin by quantitative mass spectrometry (MS), confirm specific sites within the N2Bus and PEVK spring elements of mouse and human titin, and show that CaMKII-mediated phosphorylation reduces cardiomyocyte F passive . Although titin phosphorylation by CaMKIIδ may benefit diastolic function, deranged CaMKII-dependent titin phosphorylation occurs in end-stage human HF and may contribute to the disease phenotype.
Methods
An expanded Methods section is available in the Online Data Supplement.
Heart Tissue
Left-ventricular tissue was obtained from CaMKIIδ/γ double knockout mice (DKO), the previously established and characterized CaMKIIδC-overexpressing transgenic (TG) mice, 29 and human nonfailing donor (DO) and end-stage failing hearts. Procedures were conducted in full accordance with the institutional guidelines and were approved by the respective ethics committees.
Quantitative Mass Spectrometry
We mixed equal amounts of heart tissue extracts (7.5 mg) from the 13 Lys 6 heavy-labeled stable isotope labeling by amino acids in cell culture mouse 38 and a nonlabeled wild-type (WT) or nonlabeled CaMKIIδ/γ DKO mouse. After protein digestion and phosphopeptide enrichment, the ratio of labeled:unlabeled peptides was determined by liquid chromatography and tandem MS 38 and used to identify the DKO:WT ratio of titin phosphopeptides.
Titin Analysis

Titin Isoform Separation
Homogenized myocardial samples were analyzed by 1.8% SDS-PAGE. 8 Protein bands were visualized by Sypro Ruby and analyzed densitometrically.
All-Titin Phosphorylation Assays
Titin bands were stained with Pro-Q Diamond and subsequently with Sypro Ruby, and phospho-protein signals were indexed to total-protein signals. Alternatively, all-titin phosphorylation was measured by CaMKIIδ-mediated back-phosphorylation in the presence of [γ 32 P] ATP, followed by autoradiography, as described. 8 
Nonstandard Abbreviations and Acronyms
Titin/Phosphotitin Immunoblots
Western blots were performed using custom-made, affinity-purified, phosphoserine-specific antibodies against phospho-S4010, -S4062, -S4099 (all N2Bus), -S11878, and -S12022 (both PEVK), of human titin (UniProtKB identifyer, Q8WZ42), and antibodies recognizing the corresponding nonphosphorylated sequence at these sites. We also used phosphosite-specific antibodies against phospho-S3991, -S4043, -S4080 (all N2Bus), -S12742, and -S12884 (both PEVK), of mouse titin (UniProtKB identifyer, A2ASS6).
Recombinant Titin Construct Expression and Phosphorylation
Human titin constructs, WT-N2Bus and WT or mutant PEVK (T12007A, S12009A, S12022A, or a combination thereof), were expressed recombinantly. Fragments were incubated with CaMKIIδ in the presence of [γ 32 P]ATP, and phosphorylation was detected by autoradiography.
Cardiomyocyte Force Measurements
Cardiomyocytes were skinned and single isolated cells attached between a force transducer and motor. 39 F passive was recorded over the sarcomere length (SL) range, 1.8 to 2.4 μm, and was measured before/after CaMKIIδ incubation, sometimes after preincubation with antititin antibodies.
CaMKII Expression and Activity
CaMKII expression was measured by immunoblot, CaMKII activity by nonradioactive kinase activity-assay kit (CycLex).
Prediction of CaMK-Dependent Phosphosites
The GPS program, version 2.1.1., 40 was used for predicting potential CaMK(II)-dependent phosphosites in N2Bus/PEVK titin.
Statistics
Values are given as mean±SEM. Statistically significant differences were tested using Bonferroni adjusted t test or paired Student t test, with P<0.05 considered significant.
Results
We hypothesized that the hearts of CaMKIIδ/γ DKO or TG CaMKIIδC-overexpressing mice show altered titin phosphorylation compared with matched WT hearts.
Phosphorylation of Titin Is Decreased in CaMKIIδ/γ DKO and Increased in CaMKIIδC TG
By Pro-Q-Diamond/Sypro-Ruby staining ( Figure 1A ), all-titin phosphorylation was greatly decreased, on average by ≈66%, in CaMKIIδ/γ DKO compared with WT mouse hearts ( Figure  1D ). In contrast, all-titin phosphorylation was significantly increased, on average by ≈30%, in CaMKIIδC-overexpressing TG compared with matched WT hearts ( Figure 1E ). Titinisoform composition remained unchanged in TG versus WT hearts ( Figure 1C ), but was significantly, though modestly, altered in favor of the N2BA-isoform in DKO versus WT ( Figure 1B) .
In an alternative approach, demembranated cardiac fiber bundles from these mouse heart groups were either phosphorylated ex vivo by CaMKIIδ or first dephosphorylated with alkaline phosphatase (PP) before back-phosphorylation with CaMKIIδ (PP+CaMKII), and then titin SDS-PAGE followed by autoradiography was performed ( Figure 2 ). Strong signals were obtained for the N2B-titin isoform (greatly predominant in mouse hearts) after kinase treatment. Inherent phosphorylation was calculated as the difference in phosphorylation signals between CaMKII and PP+CaMKII conditions. N2Btitin phosphorylation was significantly reduced, on average by ≈47%, in DKO versus WT (Figure 2A ) and increased by nearly 100% in TG versus WT mouse hearts ( Figure 2B ).
Cardiomyocyte F passive Is Elevated in CaMKIIδ/γ DKO and Reduced in CaMKIIδC TG Hearts
The passive length-tension relationship of single skinned cardiomyocytes in relaxing solution was steeper in CaMKIIδ/γ DKO than in WT hearts ( Figure 3A ). Significantly increased F passive levels in DKO versus WT cells were found at SL 2.0 µm or higher. In contrast, F passive of CaMKIIδC TG cardiomyocytes was significantly reduced compared with WT cells at SL 2.1 μm or higher ( Figure 3B ). 
Incubation of Cardiomyocytes With CaMKIIδ Lowers F passive in WT and DKO
Administering CaMKIIδ to nonactivated skinned cardiomyocytes from DKO hearts in relaxing solution significantly reduced F passive at SL 2.1 μm or higher to the levels found in matched WT cells ( Figure 3A ). In contrast, incubating skinned TG cardiomyocytes with CaMKIIδ had no effect on F passive ( Figure 3B ). In the respective WT cells, F passive was reduced with CaMKIIδ-treatment in the higher SL range.
Quantitative Mass Spectrometry Detects Conserved CaMKII-Phosphosites in PEVK-Titin
To identify CaMKII-dependent titin phosphorylation sites, we used quantitative MS in conjunction with a modified stable isotope labeling by amino acids in cell culture technique, 38 comparing WT and CaMKIIδ/γ DKO mouse heart tissue. Titin was among the proteins with the most frequent and largest alterations in phosphorylation in DKO compared with WT hearts. We detected 71 titin serine/threonine/tyrosine phosphopeptides (Online Table I ). Fifty-four of them were class-1 phosphopeptides (localization probability, 0.75-1.00; median >0.99), the remainder were class-2 phosphopeptides (localization probability <0.75). A ratio of DKO (mutant) versus WT phosphorylation levels (direct ratio Mut/WT; Online Table I) was obtained for 39 titin phosphopeptides, most of them with a single phosphorylation site, some also with 2 phosphosites.
With the (conservative) estimate that a Mut/WT ratio ≤0.7 or ≥1.3 indicates significant changes in DKO versus WT, we found 2 hyperphosphorylated sites in DKO hearts, S264 within a unique sequence between Ig-domain2 and Z-repeat1 in Z-disk titin (Mut/WT ratio, 1.31) and S4175 at the COOHterminus of the N2Bus within I-band titin (Mut/WT ratio, 1.30; Online Table I ). Twenty titin phosphopeptides showed no differential phosphorylation in DKO versus WT (0.7<Mut/ WT ratio<1.3). Seventeen titin phosphopeptides were hypophosphorylated in DKO (Mut/WT ratio ≤0.7), 15 with a single phosphosite and 2 showing double phosphorylation (Table) . Among them were sites from I-band titin, but also from Z-disk, A-, and M-band titin.
Focusing on the elastic I-band titin, we found 6 sites with reduced phosphorylation in DKO (Table) . They included S2896 within Ig-domain 16 (Mut/WT ratio, 0.4), S9144 within Ig-domain 74 (Mut/WT ratio, 0.59), which is not expressed in the N2B-isoform, and S4672 present only in the rare, truncated, Novex-III titin isoform (Mut/WT ratio, 0.66). Importantly, we also detected 3 hypophosphorylated sites at the COOH terminus of the PEVK-segment: S12884 (Mut/WT ratio, 0.63), T12869, and S12871, the latter of which appeared to be hypophosphorylated coordinately (Mut/WT ratio, 0.48; double phosphorylation). These 3 PEVK-sites and surrounding residues are highly conserved across a wide range of mammalian species ( Figure 4A ). Mouse T12869, S12871, and S12884 correspond to T12007, S12009, and S12022 in human titin, respectively ( Figure 4A ). The method also found 7 phosphosites in the cardiac-specific N2Bus (Online Table I ), which in mouse encompasses residues 3721 to 4251, but apart from S4175 (hyperphosphorylated in DKO hearts; see above), none of these sites (S3870 [Mut/WT ratio, 1.10], S3993, and a cluster containing T4017, S4018, T4020, S4021) is conserved in human titin.
Titin N2Bus and PEVK Fragments Are Phosphorylated by CaMKIIδ In Vitro
All PKs with a known mechanical effect on titin target residues within the N2Bus or PEVK regions. Therefore, we expressed recombinant human fragments of WT-N2Bus and WT-PEVK and tested these constructs for phosphorylation by CaMKIIδ using autoradiography. Both fragments could be readily phosphorylated in vitro ( Figure 4B and 4C). We also mutated the 3 phosphosites of the PEVK-domain found by quantitative MS to alanine, generating single point mutants (T12007A , S12009A, and S12022A), double (T12007A+S12009A) and triple mutants (T12007A+S12009A+S12022A). Compared with WT-PEVK, CaMKIIδ-mediated phosphorylation was reduced for the 3 single point mutants by ≈30%, the double mutant by ≈60%, and the triple mutant by ≈80% ( Figure 4C ), confirming that phosphorylation at these sites is CaMKIIδ-dependent.
Predicted CaMK/CaMKII-Dependent N2Bus/PEVK Phosphosites
The phosphosite prediction tool GPS (version 2.1.1) 40 confirmed that S12022/S12884 in human/mouse PEVK-titin is a high-confidence CaMK (mainly CaMKII) phosphosite (Online Table II ). Of the 2 other phospho-PEVK sites identified by quantitative phosphoproteomics, only S12009/S12871 was a predicted low-confidence CaMK-site. We also included S11878/S12742 of human/mouse PEVK-titin, a known PKCα-dependent phosphosite, 18 but this serine was not predicted to be phosphorylated by CaMK/CaMKII. Within the N2Bus, the GPS program found various potential low-confidence CaMK-phosphosites. We focused on 3 interspeciesconserved serines, which we detected in MS screens of recombinantly expressed N2Bus as being phosphorylated by different PKs (data not shown): S4010/S3991, S4062/S4043, and S4099/S4080, of human/mouse titin. For S4010/S3991 and S4099/S4080, CaMK-related phosphorylation propensity was predicted to be very low or absent, whereas S4062/S4043 is a predicted low-confidence (human) or medium-confidence (mouse) CaMK-phosphosite (Online Table II ).
Site-Specific Phosphorylation at N2Bus/PEVK Regions Is Altered in DKO and TG Hearts
Affinity-purified phosphospecific antibodies were generated against conserved serines of human/mouse N2Bus at S4062/S4043 (potentially CaMK-dependent), S4010/S3991, and S4099/S4080 (both unlikely CaMK-sites), as well as human/mouse PEVK at S11878/S12742 (probably not CaMK-dependent) and S12022/S12884 (confirmed CaMKIIdependent). Site-specific titin phosphorylation was studied by Western blot in CaMKIIδ/γ DKO, CaMKIIδC TG, and matched WT mouse hearts. With each phosphospecific antibody, a corresponding sequence-specific antibody was used to monitor protein loading ( Figure 5 ).
In DKO versus WT, phosphorylation was unaltered at S3991 and S12742, but significantly decreased at S4043, S4080, and S12884 ( Figure 5A and 5B). The largest reduction was observed at S4043 and S12884. In TG versus WT, phosphorylation was unaltered at S4080, S12742, and S12884, but significantly increased at S3991 and S4043 ( Figure 5C and 5D ). Taken together, site-specific N2Bus/PEVK phosphorylation was reduced or unaltered in DKO and increased or unaltered in TG hearts. Considering that some CaMKII-phosphosites may already be saturated in WT mouse titin, which could explain a lack of effect in CaMKIIδ-overexpressing TG hearts, we propose that S4043 (N2Bus) and S12884 (PEVK) are primary CaMKII-sites, whereas S3991 (N2Bus) and S12742 (PEVK) are probably not phosphorylated by CaMKII. S4080 (N2Bus) is unlikely, but cannot be ruled out, as a CaMKII-phosphosite.
Blunting CaMKII-Mediated Titin Phosphorylation Using Sequence-Specific Titin Antibodies Attenuates the CaMKIIδ Effect on Cardiomyocyte F passive
We assumed that sequence-specific antibodies to N2Bus/ PEVK at the identified CaMKII-dependent phosphosites may partially block CaMKII-mediated phosphorylation of titin in cardiomyocytes. Indeed, the CaMKIIδ-induced increase in all-titin (ex vivo) phosphorylation was blunted on incubating skinned WT mouse heart tissue (pretreated with alkaline phosphatase) with a mix of 2 antimouse titin antibodies against the sequences QELLSKETLFP (N2Bus; includes S4043) and KLRPGSGGEKPP (PEVK; includes S12884), respectively ( Figure 6A ). As a control, the tissue was incubated with antihuman titin antibodies to sequence EGPRIQQGAKTSLQEEMDS (N2Bus), which does not recognize mouse titin, as this sequence is not conserved in the mouse. This nonspecific antibody did not prevent a significant CaMKIIδ-induced increase in all-titin phosphorylation ( Figure 6B ). Furthermore, incubating single skinned mouse cardiomyocytes with the antimouse titin antibody mix attenuated the decrease in F passive on CaMKIIδ treatment ( Figure 6C ). No such blunting effect was found when the cardiomyocytes were incubated with the nonbinding antihuman titin antibody ( Figure 6D ). These results suggest that CaMKII-dependent phosphorylation at S4043 or S12884 or both modulates titinbased F passive .
Deranged Phosphorylation at CaMKII-Sites of Titin-N2Bus/PEVK in Failing Human Hearts
To address a possible pathophysiological significance of CaMKII-mediated phosphorylation at identified titin phosphosites, we compared phosphorylation at S4010, S4062, S4099 (all human N2Bus), S11878, and S12022 (both human PEVK) between nonfailing DO hearts and end-stage failing transplant hearts (HF) by immunoblot analysis using phosphosite-specific antibodies ( Figure 7A and 7B ). Significantly increased phosphorylation in HF versus DO was observed at S4010, S4062, and S11878, whereas S12022 showed a clear trend toward hyperphosphorylation in HF ( Figure 7A and 7B) .
No significant alterations were detected at S4099. Notably, phosphosite-specific antibodies against S4062 and S12022 detected strong signals when we incubated recombinant human N2Bus-WT and PEVK-WT fragments, respectively, with CaMKIIδ (Online Figure I) . In HF versus DO hearts, we found both the expression and the activity of CaMKII to be approximately doubled ( Figure 7C ). In summary, several I-band titin sites were hyperphosphorylated in human HF, including confirmed CaMKIIδ-dependent phosphosites, consistent with the increased expression/activity of CaMKII in these hearts.
Discussion
CaMKII plays a crucial role in the physiology and pathophysiology of cardiomyocytes, modulating both systolic and diastolic properties by phosphorylating ion channels, Ca 2+ -handling proteins, and chromatin-modifying enzymes. 23, [25] [26] [27] [28] Increased expression and activity of CaMKIIδ has frequently (though not consistently) been reported in HF, including hypertrophic heart disease. 23, 24, [26] [27] [28] Multiple evidence suggests the kinase is centrally involved in regulating the cardiac hypertrophic gene program. 25, 30, 41, 42 Deletion of CaMKIIδ in mice blunts cardiac hypertrophy from increased afterload 30 and a mechanical stress-induced transition to overt HF. 31 Based on the beneficial effects of CaMKII-inhibition on cardiac remodeling in hypertrophy and HF, the kinase has been proposed as a potential therapeutic target. 43 Although less well established, CaMKII also modulates phosphorylation and function of sarcomeric regulatory proteins, such as cardiac myosin-binding protein-C and cardiac troponin-I. [34] [35] [36] [37] A role for CaMKII in myofilament protein phosphorylation may underlie part of the deterioration in diastolic function reported in pressure-overload CaMKIIδknockout mice. 37 In this work, we demonstrated that the myofilament protein titin is a main substrate of CaMKII. All-titin phosphorylation was significantly reduced in CaMKIIδ/γ DKO and increased in CaMKIIδC-overexpressing TG compared with WT mouse hearts. However, alterations in all-titin phosphorylation reflect modifications at potentially hundreds of amino acids within the giant titin protein and methods are needed which detect site-specific phosphorylation. In a quantitative MS screen using the stable isotope labeling by amino acids in cell culture mouse heart, 38 we detected titin among the cardiac proteins most highly affected in their phosphorylation state by CaMKIIδ/γ deletion. Many of the phosphosites found in titin are located within the Z-disk, A-band, or M-band sections of the molecule, where they could be involved in protein-protein interactions or mechanical signaling. Because we were interested in potential mechanical effects of CaMKIIphosphorylation on F passive , and because phosphorylation of elastic I-band titin regions affects cardiomyocyte F passive , 8, 18, 19 we focused on CaMKII-dependent phosphosites within I-band titin. Conserved CaMKII-sites were identified within the N2Bus and PEVK spring elements present in N2BA and N2B cardiac titin isoforms, and CaMKIIδ-mediated phosphorylation lowered cardiomyocyte F passive . End-stage failing human hearts revealed higher phosphorylation at CaMKII-dependent titin sites than nonfailing DO hearts, possibly contributing to the mechanical dysfunction in HF. Our work establishes a previously unknown role for CaMKIIδ in regulating diastolic passive properties of healthy and diseased hearts.
Various PKs modulate passive stiffness by phosphorylating titin. 8, [17] [18] [19] [20] [21] Phosphorylation of the N2Bus-element can be mediated by PKA, PKG, or ERK2, and this modification always appears to reduce F passive . 3, 7, 8, [17] [18] [19] [20] [21] [22] We earlier suggested that the PKG-effect is brought about by an increased bending rigidity (parameterized by the persistence length) of the N2Bus in the phosphorylated versus unphosphorylated state. 8 Specific N2Bus-sites phosphorylated by PKA, PKG, and ERK2 are only beginning to be uncovered. PKA and PKG phosphorylate the same residue in the human N2Bus, S4185 of full-length human titin (UniProtKB identifyer, Q8WZ42), but this site is not conserved in the N2Bus-element of other mammals. 8 However, because rat, 19 cow, 20 and presumably also dog 22 N2Bus can readily be phosphorylated by PKA or PKG, it is likely that other (perhaps conserved) PKA/PKG-phosphosites are present within this titin segment. With regard to ERK2, key phosphosites in the human N2Bus are S3918 (not conserved), S3960 (not conserved), and S4010 (conserved; positions according to UniProtKB identifyer, Q8WZ42). 21 Moreover, phosphorylation also occurs at the PEVK spring element, where 2 conserved residues, S11878 and S12022 (of human titin), can be phosphorylated by PKCα, with S11878 as the primary site. 18 PKCα-mediated phosphorylation of PEVK-sites increases F passive , an effect explainable by a reduced persistence length of PEVK-domain in the phosphorylated state. 18 We provided multiple evidence that CaMKII phosphorylates the PEVK-domain at S12022/S12884 (of human/mouse titin): (1) 37% reduction of phospho-S12884 in CaMKIIδ/γ DKO versus WT mouse heart by quantitative MS; (2) >60% signal-reduction in DKO versus WT by Western blot using antiphospho-S12884 antibodies; (3) ≈30% signal-reduction in CaMKIIδ-phosphorylated human PEVK-mutant S12022A versus PEVK-WT recombinant fragment by autoradiography; (4) Highest confidence of all examined N2Bus/PEVK motifs in GPS-based searches for predicted CaMK/CaMKIIphosphosites; and (5) Phosphorylation at S12022 tended to be increased in human HF versus DO hearts, concomitant with elevated CaMKII expression and activity in the end-stage failing hearts. Most likely, phosphorylation at S12022/S12884 mediates part of the mechanical effect of CaMKIIδ on F passive .
Our results suggested additional conserved CaMKIIphosphosites within the PEVK-region, T12007/T12869 and S12009/S12871 of human/mouse titin, which in the MS screen appeared to be downregulated in DKO coordinately. These 2 sites were confirmed to be phosphorylated by CaMKIIδ in vitro. The main PKCα-phosphosite of mouse PEVK, S12742, 18 was unaltered in DKO or TG, but the corresponding human site at S11878 showed increased phosphorylation in HF versus DO hearts. Neither mouse S12742 nor human S11878 are . Effect of Ca 2+ /calmodulin-dependent protein kinase-II (CaMKII) δ on all-titin phosphorylation and passive tension of skinned mouse cardiomyocytes after incubation with antititin antibodies. A and B, All-titin phosphorylation by Pro-Q-Diamond/Sypro-Ruby staining in wild-type (WT) mouse heart tissue, before (Ctrl) and after alkaline phosphatase (PP) treatment, followed by CaMKIIδ-incubation (+CaMK). A, Dephosphorylated tissue was incubated before back-phosphorylation with a mix of 2 antimouse titin antibodies (Abs) to sequence QELLSKETLFP (N2B-unique sequence [N2Bus]; includes S4043) and KLRPGSGGEKPP (PEVK; includes S12884), respectively. B, Dephosphorylated tissue was incubated before back-phosphorylation with antihuman titin antibody to sequence EGPRIQQGAKTSLQEEMDS (N2Bus), which does not bind mouse titin (nonbinding [n-b] Ab). Antibody concentrations, 1:50. *P<0.05 in Bonferroni adjusted t test. C and D, Passive tension (F passive ) of single cardiomyocytes, before (Ctrl) and after PP treatment, followed by CaMKIIδ-incubation (+CaMK). Treatment conditions in C are as in A, and in D as in B; also included is the dephosphorylated state before antibody incubation (+PP). E, CaMKIIδ-induced F passive reduction, calculated from the difference between the red and green curves in C and the pink and blue curves in D, respectively. Fit curves are 2-order polynomials to the means, except the green curve in E, which is a linear fit. Data are mean±SEM; n=4/group; *P<0.05 in Student t test, for +PP vs Ctrl in C and D, and CaMKII effect+Abs vs CaMKII effect+n-b Ab in E; #P<0.05, for +PP+n-b Ab vs +PP+n-b Ab+CaMKII in D. February 15, 2013 predicted CaMK-phosphosites, suggesting these residues may be phosphorylated in vivo by PKCα rather than CaMKII. The hyperphosphorylation at S11878 in human HF could then be related to increased PKCα expression/activity, which is a frequent observation in failing hearts. 44 Interestingly, phospho-S11878/S12742 levels were reported to be elevated in failing versus nonfailing mouse hearts, whereas phospho-S12022/ S12884 levels were reduced. 45 An issue to be addressed in future work is the significant cross-talk that exists between the PKCα and CaMKII pathways. 46 Activation of 1 pathway could well affect the phosphorylation of titin sites predominantly phosphorylated via the cross-talking pathway. In summary, S12022/S12884 is the key CaMKIIδ-phosphosite in the constitutively expressed human/mouse PEVK-domain, which can modulate titin stiffness, but additional CaMKII-sites are present in this region. Some PEVK-sites phosphorylated by CaMKII may have a propensity for phosphorylation by other kinase(s), especially PKCα.
Although our quantitative phosphoproteome screen identified several phosphosites within the cardiac N2Bus spring element, CaMKII-dependent sites were not among them. However, recombinant human N2Bus was phosphorylated by CaMKIIδ. Antibodies to conserved N2Bus phospho-serines detected reduced phosphorylation in DKO versus WT mouse hearts at S4043 and S4080 (but not S3991), whereas phosphosignals at S3991 and S4043 (but not S4080) were increased in TG. The corresponding human phospho-S4010 and -S4062 (but not -S4099) were elevated in failing versus DO hearts. Because S4010/S3991 of human/mouse titin is phosphorylated by ERK2, 21 increased phospho-S3991 in TG mouse hearts could be attributable to overactivation of this kinase, which occurs in cardiomyocytes in response to many different stimuli. 47 ERK2activation is a known factor in pathological cardiac growth, which could also explain the elevated phospho-S4010 levels in the failing human hearts. The CaMKII and ERK1/2 pathways interact in several ways (while cross-talking to the PKCα pathway). 46 Furthermore, there is synergy between the CaMKII and PKA pathways, 27, 48 and the latter also targets titin-N2Bus. 17, 19, 20 Altering CaMKII expression/activity is thus likely to have secondary effects on the expression/activity of other PKs, with consequences for N2Bus-phosphorylation. Considering that S4062 is phosphorylated by CaMKIIδ in vitro, and taking into account the GPS-based predictions for N2Bus-phosphosites, S4010/S3991 and S4099/S4080 in human/mouse N2Bus are unlikely to be CaMKII-dependent phosphosites, whereas S4062/S4043 is a promising candidate site.
Finally, we found elevated mouse cardiomyocyte F passive in DKO and reduced F passive in TG, compared with WT. Incubating the skinned cardiomyocytes with CaMKIIδ lowered F passive in DKO and WT, but had no effect on TG cells. Blocking CaMKII-mediated titin phosphorylation at N2Bus/PEVK sites using sequence-specific antititin antibodies on the mouse cardiomyocytes prevented the CaMKII-induced drop in F passive . Thus, CaMKIIδ alters F passive in the same direction as PKA, PKG, and ERK2 do on phosphorylating the N2Bus. 3, 8, 17, [19] [20] [21] PKCα so far remains the only kinase with a stiffening effect on titin. 18 Expression and activity of PKA and PKG are reduced in failing hearts, 39 whereas those of PKCα, ERK2, and CaMKIIδ are frequently increased. In a set of human failing hearts similar to the one used by us, cardiomyocyte F passive was unaltered compared with nonfailing DO hearts, but sitespecific titin phosphorylation was not measured. 49 Elsewhere, cardiomyocyte F passive was found to be pathologically elevated in human HFpEF or HFrEF, and phosphorylation by PKA or PKG normalized F passive . 3, 7, 22 Similarly, inhibiting PKCα activity might reduce F passive . 18, 45 Less obvious is whether CaMKIIinhibition as a potential therapeutic approach in HF 37,43 may be beneficial to cardiomyocyte function, at least with regard to the mechanical roles of titin. Reducing CaMKII-mediated titin phosphorylation would increase F passive and be detrimental to diastolic filling. At the same time, a stiffer titin spring could speed up diastolic recoil 13 and amplify some of the mechanosensory functions of titin. [12] [13] [14] 
Conclusions
Our study identifies a novel pathway that modulates titinbased passive myocardial stiffness via CaMKIIδ-mediated phosphorylation of titin N2Bus and PEVK spring elements. Multiple evidence establishes S12022/S12884 in human/ mouse PEVK-domain as a key CaMKII-phosphorylation site and S4062/S4043 within the N2Bus-element as another highconfidence CaMKII-site. CaMKII-mediated phosphorylation at these titin regions reduces cardiomyocyte F passive and benefits diastolic filling. Deranged CaMKIIδ-mediated titin phosphorylation occurs in end-stage failing human hearts, likely contributing to altered cardiomyocyte mechanical properties and compromised cardiac function.
